Function Health Raises $298M Oversubscribed Series B at $2.5B Valuation, Launches AI-Powered Medical Intelligence Lab
By Lena Chen, Tech Health Editor
November 20, 2025
Function Health, the San Francisco-based preventive health startup that’s redefining routine lab testing with comprehensive biomarker panels, has closed a whopping $298 million Series B funding round at a $2.5 billion post-money valuation. The oversubscribed raise, led by Redpoint Ventures with participation from Andreessen Horowitz (a16z), Scale Venture Partners, and a star-studded roster of high-profile individuals including NBA athletes and celebrities, marks the company’s unicorn status and brings total funding to $350 million since its 2022 founding. The capital will supercharge the rollout of its new Medical Intelligence Lab, an AI-driven platform fusing lab data with expert insights to empower users toward longer, healthier lives.
From Seed to Unicorn: A Rapid Ascent in Preventive Health
Launched in 2022 by a team including health influencer and functional medicine pioneer Dr. Mark Hyman, Function Health has quickly carved out a niche in the booming longevity and personalized medicine space. The company’s core offering—a bi-annual panel testing over 100 biomarkers, from hormones and heart health markers to nutrient levels and inflammation indicators—costs $499 annually and provides users with a “longitudinal view” of their biology, complete with clinician-reviewed action plans. Unlike traditional annual checkups that skim the surface with just five to 10 metrics, Function’s approach aims to catch issues early, appealing to a growing demographic of proactive consumers obsessed with optimization.
The startup’s traction is undeniable: Over 400,000 members have signed up, generating buzz through word-of-mouth and endorsements from A-listers like Will Ferrell, Kristen Bell, and tech execs. Early funding included a $10 million seed in 2023 from a16z and Thrive Capital, followed by partnerships with Quest Diagnostics for lab fulfillment. By mid-2025, Function reported 200% year-over-year membership growth, fueled by integrations with wearables like Oura and Whoop for holistic data aggregation. This Series B, which closed in under three months, reflects investor confidence in a market projected to hit $1.2 trillion globally by 2030, per McKinsey’s longevity report.
Dr. Hyman, Function’s co-founder and a 15-time New York Times bestselling author, framed the raise as a pivot point: “We’re not just testing; we’re building the operating system for human health.” The valuation leap—from a rumored $500 million pre-money in earlier talks—positions Function ahead of peers like Levels Health ($300M valuation) and Everlywell (acquired for $1.9B in 2023).
Medical Intelligence Lab: AI Meets Biomarkers for Personalized Longevity
The headline-grabber here is the launch of Function’s Medical Intelligence Lab, a proprietary AI system that ingests users’ lab results, genetic data, and lifestyle inputs to deliver hyper-personalized recommendations. Think ChatGPT for your bloodwork: An interactive chatbot that explains results in plain language, flags risks like prediabetes or thyroid imbalances, and suggests tailored interventions—from supplement stacks to dietary tweaks—vetted by a network of 50+ clinicians.
Powered by custom large language models trained on anonymized health datasets, the lab aims to “democratize medical expertise,” according to CEO Jonathan Swerdlin. Early beta users report 80% higher engagement, with features like predictive modeling for disease trajectories (e.g., “Your ferritin levels suggest a 25% elevated heart risk in five years—here’s how to mitigate”). The platform also integrates with electronic health records (EHRs) for seamless doctor handoffs, addressing a key pain point in consumer health tech.
This isn’t pie-in-the-sky: Function’s AI builds on partnerships with Google Cloud for data processing and a clinical advisory board stacked with MDs from Mayo Clinic and Stanford. The funding will accelerate global expansion, starting with Canada and the UK in Q1 2026, where regulatory hurdles for direct-to-consumer testing are easing.
Funding Breakdown: Redpoint Leads with Celeb and VC Heavyweights
Redpoint Ventures, fresh off bets on Ramp and Notion, anchored the round with a $100 million check, citing Function’s “defensible moat” in data aggregation and AI personalization. a16z doubled down from its seed investment, while new backers like Scale and NBA stars (including Kevin Durant and Draymond Green) added glamour and domain expertise. Celebrities have been pouring in since the seed: Colin Kaepernick, Zac Efron, Pedro Pascal, and Matt Damon joined earlier, drawn to Hyman’s vision of “health as performance.”
The oversubscription—closing 20% above target—signals frothy demand for health AI amid a post-pandemic wellness boom. Function’s revenue model, blending subscriptions with B2B licensing to employers and insurers, hit $50 million ARR in 2025, with 60% gross margins thanks to scalable lab partnerships. Exit comps? Think Peloton’s early days or 23andMe’s peak, but with stickier consumer habits.
- Key Funding Details:
- Round Size: $298 million (oversubscribed)
- Valuation: $2.5 billion post-money
- Lead Investor: Redpoint Ventures ($100M+)
- Notable Backers: a16z, Scale Venture Partners, Kevin Durant, Draymond Green, Will Ferrell, Kristen Bell
- Total Raised: $350 million since 2022
- Use of Funds: AI development (40%), international expansion (30%), clinician network growth (20%), marketing (10%)
- Growth Metrics:
- Members: 400,000+ (200% YoY growth)
- Biomarkers Tested: 100+ per panel ($499/year)
- AI Engagement: 80% uplift in beta; predictive modeling for 50+ conditions
- Revenue: $50M ARR, 60% margins
- Expansion: Canada/UK launch Q1 2026
Market Context: Riding the Longevity Wave Amid Regulatory Scrutiny
Function enters a red-hot sector where AI-health crossovers are minting unicorns left and right. Competitors like InsideTracker (biomarker-focused) and Viome (gut microbiome testing) lag in valuation, but giants like Google Fitbit and Apple Health are circling with data plays. The raise aligns with a 25% uptick in VC for preventive health in 2025, per PitchBook, driven by aging demographics and post-COVID health anxiety.
Challenges? FDA oversight on AI diagnostics looms, with Function classifying its tools as “wellness” to sidestep stricter regs—for now. Privacy advocates flag data aggregation risks, but the company’s HIPAA-compliant platform and opt-in AI training mitigate concerns. Hyman, a vocal critic of “sick care” systems, positions Function as a disruptor: “We’re shifting from reactive medicine to proactive mastery.”
On X, the announcement sparked 12,000+ mentions, with tech influencers like @pmarca (a16z’s Marc Andreessen) tweeting: “Health data is the new oil—Function is refining it into gold.” Skeptics quipped about “biomarker overload,” but user testimonials flooded in, praising actionable insights.
Function Health’s $2.5 billion milestone isn’t just a funding flex—it’s validation for a paradigm where AI turns blood tests into life blueprints. With $298 million in the bank, the startup is poised to scale its Medical Intelligence Lab from niche tool to global standard, potentially adding years to users’ healthspans. As Dr. Hyman puts it, this is about “100 healthy years for everyone.” If they deliver, investors—and the world—might just buy in.